SEARCH

SEARCH BY CITATION

Bibliography

  • 1
    Truelove SC & Witts LJ. Cortisone in ulcerative colitis: Final report on a therapeutic trial. Br Med J 1955; 5: 10418.
  • 2
    Litchiger S, Present DH & Kornbluth DH, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New Engl J Med 1994; 330: 19415.
  • 3
    Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol 1996; 91: 42333.
  • 4
    Flanagan WM, Corthesy B & Bram RJ, et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 8037.
  • 5
    Stephens J, Goldstein R & Crippin J, et al. Effect of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc 1993; 25: 11223.
  • 6
    Van Thiel DH, Carroll P & Abu-Elmagd K, et al. Tacrolimus (FK 506) treatment for primary sclerosing cholangitis: Result of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 4559.
  • 7
    Kitis G, Wright HI & Abu-Elmagd K. The course of inflammatory bowel disease under FK 506 immunosuppression after liver transplantation for primary sclerosing cholangitis. Gut 1993; 34(Suppl. 3): S26S26(Abstract).
  • 8
    Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 4863.
  • 9
    Hinterleitner TA, Petritsh W & Aichbichler B, et al. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn’s disease. Z Gastroenterol 1997; 35: 6038.
  • 10
    Hanauer SB & Smith MB. Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993; 88: 6469.
  • 11
    Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol 1997; 92: 8769.
  • 12
    Bousvaros A, Leichtner AM & Book L, et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK 506). Gastroenterology 1996; 111: 23743.
  • 13
    D'Ambrosio R, Girzaitis N & Jusko WJ. Multicenter comparisons of Tacrolimus (FK506) whole blood concentrations as measured by the Abbott IM, analyzer and enzyme immunoassay with methylene chloride extraction. Ther Drug Monit 1994; 16: 28792.
  • 14
    Guyatt G, Mitchell A & Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel diseases. Gastroenterology 1989; 96: 80410.
  • 15
    Munckholm A, Langholz E & Davidsen M, et al. Frequency of glucocorticoid resistance or dependency in Crohn’s disease. Gut 1994; 35: 3602.
  • 16
    Travis SPL, Farrant JM & Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 90510.
  • 17
    Sandborn WJ, Tremaine WJ & Batts KP, et al. Pouchitis after ileal anal pouch anastomosis: a pouchitis disease actvity index. Mayo Clin Proc 1994; 69: 40915.
  • 18
    Hyde GM, Thilainaygam Av & Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: Time for a reappraisal? Gastroenterology 1997; 112: A1002A1002 (Abstract).
  • 19
    Carbonnel F, Boruchowicz A & Duclos B, et al. Intravenous cyclosprin in attacks of ulcerative colitis. Dig Dis Sci 1996; 11: 24716.
  • 20
    Stange EF, Modigliani R & Pena AS, et al. European trial of cyclosporine in chronic active Crohn′ s disease: a 12 month study. The European Study Group. Gastroenterology 1995; 109: 77482.
  • 21
    Feagan BG, McDonald JW & Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial Investigators. New Engl J Med 1994; 330: 184651.
  • 22
    Baker K & Jewell DP. Cyclosporin for the treatment of severe inflammatory bowel disease. Aliment Pharmacol Ther 1989; 3: 1439.
  • 23
    Brynskov J, Freud L & Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. New Engl J Med 1989; 321: 84550.
  • 24
    Cohen RD, Stein R & Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 158792.
    Direct Link:
  • 25
    Futren G & Mihatsch MJ. For the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine induced nephropathy in patients with autoimmune diseases. New Engl J Med 1992; 326: 165460.
  • 26
    Jain AB, Venkataramanan R & Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990; 22(Suppl. 1): 579.
  • 27
    Befeler AS, Lissoos TW & Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65: 3936.
  • 28
    Fellermann K, Ludwing D & Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroentrol 1998; 93: 18606.
    Direct Link:
  • 29
    Ierardi E, Principi M & Rendina M, et al. Oral tacrolimus (FK 506) in Crohn’s disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000; 30: 2002.
  • 30
    Bismuth H. for the European FK 506 Multicenter liver Study Group. Comparison of FK 506 and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. Transplant Proc 1995; 27: 459.
  • 31
    Targan SR, Van Hanauer SB & Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. New Engl J Med 1997; 337: 102935.
  • 32
    Singh N, Gayowski T & Wagener M, et al. Infectious complications in liver transplant recipients on Tacrolimus. Prospective analysis of 88 consecutive liver transplants. Transplantation 1994; 58: 7748.